Furiex Pharmaceuticals Short Interest Down 57.4% in May (FURX)
Furiex Pharmaceuticals (NASDAQ:FURX) was the target of a significant drop in short interest in May. As of May 15th, there was short interest totalling 312,287 shares, a drop of 57.4% from the April 30th total of 732,517 shares, StockRatingsNetwork.com reports. Approximately 4.1% of the company’s stock are short sold. Based on an average daily volume of 323,412 shares, the short-interest ratio is presently 1.0 days.
Furiex Pharmaceuticals (NASDAQ:FURX) opened at 104.19 on Thursday. Furiex Pharmaceuticals has a one year low of $32.05 and a one year high of $121.97. The stock has a 50-day moving average of $98.80 and a 200-day moving average of $75.41. The company’s market cap is $1.126 billion.
Furiex Pharmaceuticals (NASDAQ:FURX) last released its earnings data on Wednesday, May 7th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by $0.62. The company had revenue of $6.40 million for the quarter, compared to the consensus estimate of $10.01 million. During the same quarter in the previous year, the company posted $0.82 earnings per share. The company’s revenue for the quarter was down 83.7% on a year-over-year basis. Analysts expect that Furiex Pharmaceuticals will post $-2.57 EPS for the current fiscal year.
Furiex Pharmaceuticals, Inc is a drug development collaboration company. The Company’s product pipeline includes two marketed products and three programs in development, including late-stage compounds, in multiple therapeutic areas.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.